Showing posts with label Radiation. Show all posts
Showing posts with label Radiation. Show all posts

Thursday, 30 March 2023

 

Optimising post-operative radiation therapy after oncoplastic and reconstructive procedures

by Trine Tramm, Orit Kaidar-Person 

The Breast: Published: March 28, 2023

Abstract

Surgical techniques for breast cancer have been refined over the past decades to deliver an aesthetic outcome as close as possible to the contralateral intact breast. Current surgery further allows excellent aesthetic outcome even in case of mastectomy, by performing skin sparing or nipple sparing mastectomy in combination with reconstruction. In this review we discuss how to optimise post-operative radiation therapy after oncoplastic and breast reconstructive procedures, including dose, fractionation, volumes, surgical margins, and boost application.

Highlights

• New surgical procedures for breast cancer poses new challenges for the radiation oncologists.

• Oncoplastic breast surgery may question the ability to apply or the need for a tumour bed boost.

• Skin sparing/nipple sparing mastectomies should be planned to assure clear superficial margins.

• Radiation therapy indications, target volumes, dose and fractionation should be adapted per case to provide maximal clinical benefit and reduce toxicity.

• Multidisciplinary teamwork is needed from the time of diagnosis to plan the most appropriate locoregional therapy.

Thursday, 17 June 2021

Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy

 

Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy

 

by Won Kyung Cho, Jee Suk Chang, Seung Gyu Park, Nalee Kim, Doo Ho Choi, Haeyoung Kim, Yong Bae Kim, Won Park, Chang Ok Suh 

 

The Breast: VOLUME 59, P37-43, OCTOBER 01, 2021

 

Background

It is important to continually reevaluate the risk/benefit calculus of internal mammary node irradiation (IMNI) in the era of modern systemic therapy. We aimed to investigate the effect of IMNI on survival in node-positive breast cancer treated with mastectomy and anthracycline plus taxane-based chemotherapy.

Methods

We analyzed 348 patients who underwent mastectomy and anthracycline plus taxane-based chemotherapy for node-positive breast cancer between January 2006 and December 2011. All patients received postoperative radiation therapy (RT) with IMNI (n = 105, 30.2%) or without IMNI (n = 243, 69.8%). The benefit of IMNI for disease-free survival (DFS) and overall survival (OS) was evaluated using multivariate analysis and inverse probability of treatment weighting (IPTW) to adjust for unbalanced covariates between the groups.

Results

After a median follow-up of 95 months, the 10-year locoregional recurrence-free survival rate, DFS, and OS in all patients were 94.8%, 77.4%, and 86.2%, respectively. The IPTW-adjusted hazard ratio (HR) for the association of IMNI (vs. no IMNI) with DFS and OS was 0.208 (95% confidence intervals (CI) 0.045–0.966) and 0.460 (95% CI, 0.220–0.962), respectively. In multivariate analysis, IMNI was a favorable factor for DFS (HR, 0.458; P = 0.021) and OS (HR 0.233, P = 0.018).

Conclusions

IMNI was associated with improved DFS and OS in node-positive patients treated with mastectomy, post-mastectomy RT, and taxane-based chemotherapy, although the rate of locoregional recurrence was low.